JSC Kalceks launches Oxycodone 10 mg/ml and 50 mg/ml solution for injections/infusions
JSC Kalceks starts production and commercialization of Oxycodone Kalceks 10 mg/ml and 50 mg/ml solution for injections/infusions. Product has been registered via decentralized registration procedure involving 13 European Union countries. First sales are expected in Germany, Netherlands, Latvia, Estonia following by other EU countries.
Oxycodone is a semisynthetic opioid for the treatment of moderate to severe pain in patients with cancer and postoperative pain, and for the treatment of severe pain requiring the use of a strong opioid. Oxycodone Kalceks is indicated in adults only.
Oxycodone is comparable to morphine in management of moderate to severe cancer pain, with fewer side effects and faster acting than morphine. It is suggested to be used in patients who have difficulty tolerating morphine and methadone.
Oxycodone Kalceks 10 mg/ml and 50 mg/ml solution for injections/infusions is a second new product that Kalceks launches within this year.